Research programme: liver disorders therapeutics - INVENT Pharmaceuticals
Latest Information Update: 02 Aug 2023
At a glance
- Originator INVENT Pharmaceuticals
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Hepatic fibrosis; Liver cirrhosis
Most Recent Events
- 14 Jul 2023 Investigation in Hepatic fibrosis in USA (PO) (INVENT Pharmaceuticals pipeline, July 2023)
- 14 Jul 2023 Investigation in Liver cirrhosis in USA (PO) (INVENT Pharmaceuticals pipeline, July 2023)